Cargando…
TB case fatality and recurrence in a private sector cohort in Mumbai, India
BACKGROUND: Half of India’s three million TB patients are treated in the largely unregulated private sector, where quality of care is often poor. Private provider interface agencies (PPIAs) seek to improve private sector quality of care, which can be measured in terms of case fatality and recurrence...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union Against Tuberculosis and Lung Disease
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412104/ https://www.ncbi.nlm.nih.gov/pubmed/34802496 http://dx.doi.org/10.5588/ijtld.21.0266 |
_version_ | 1783747392444563456 |
---|---|
author | Huddart, S. Ingawale, P. Edwin, J. Jondhale, V. Pai, M. Benedetti, A. Shah, D. Vijayan, S. |
author_facet | Huddart, S. Ingawale, P. Edwin, J. Jondhale, V. Pai, M. Benedetti, A. Shah, D. Vijayan, S. |
author_sort | Huddart, S. |
collection | PubMed |
description | BACKGROUND: Half of India’s three million TB patients are treated in the largely unregulated private sector, where quality of care is often poor. Private provider interface agencies (PPIAs) seek to improve private sector quality of care, which can be measured in terms of case fatality and recurrence rates. METHODS: We conducted a retrospective cohort survey of 4,000 private sector patients managed by the PATH PPIA between 2014 and 2017. We estimated treatment and post-treatment case-fatality ratios (CFRs) and recurrence rates. We used Cox proportional hazards models to identify predictors of fatality and recurrence. Patient loss to follow-up was adjusted for using selection weighting. RESULTS: The treatment CFR was 7.1% (95% CI 6.0–8.2). At 24 months post-treatment, the CFR was 2.4% (95% CI 1.7–3.0) and the recurrence rate was 1.9% (95% CI 1.3–2.5). Treatment fatality was associated with age (HR 1.02, 95% CI 1.02–1.03), clinical diagnosis (HR 0.61, 95% CI 0.45–0.84), treatment duration (HR 0.09, 95% CI 0.06–0.10) and adherence. Post-treatment fatality was associated with treatment duration (HR 0.87, 95% CI 0.79–0.91) and adherence. CONCLUSIONS: We found a moderate treatment phase CFR among PPIA-managed private sector patient with low rates of post-treatment fatality and recurrence. Routine monitoring of patient outcomes after treatment would strengthen PPIAs and inform future post TB interventions. |
format | Online Article Text |
id | pubmed-8412104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | International Union Against Tuberculosis and Lung Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-84121042021-09-03 TB case fatality and recurrence in a private sector cohort in Mumbai, India Huddart, S. Ingawale, P. Edwin, J. Jondhale, V. Pai, M. Benedetti, A. Shah, D. Vijayan, S. Int J Tuberc Lung Dis Original Articles BACKGROUND: Half of India’s three million TB patients are treated in the largely unregulated private sector, where quality of care is often poor. Private provider interface agencies (PPIAs) seek to improve private sector quality of care, which can be measured in terms of case fatality and recurrence rates. METHODS: We conducted a retrospective cohort survey of 4,000 private sector patients managed by the PATH PPIA between 2014 and 2017. We estimated treatment and post-treatment case-fatality ratios (CFRs) and recurrence rates. We used Cox proportional hazards models to identify predictors of fatality and recurrence. Patient loss to follow-up was adjusted for using selection weighting. RESULTS: The treatment CFR was 7.1% (95% CI 6.0–8.2). At 24 months post-treatment, the CFR was 2.4% (95% CI 1.7–3.0) and the recurrence rate was 1.9% (95% CI 1.3–2.5). Treatment fatality was associated with age (HR 1.02, 95% CI 1.02–1.03), clinical diagnosis (HR 0.61, 95% CI 0.45–0.84), treatment duration (HR 0.09, 95% CI 0.06–0.10) and adherence. Post-treatment fatality was associated with treatment duration (HR 0.87, 95% CI 0.79–0.91) and adherence. CONCLUSIONS: We found a moderate treatment phase CFR among PPIA-managed private sector patient with low rates of post-treatment fatality and recurrence. Routine monitoring of patient outcomes after treatment would strengthen PPIAs and inform future post TB interventions. International Union Against Tuberculosis and Lung Disease 2021-09-01 2021-09-01 /pmc/articles/PMC8412104/ /pubmed/34802496 http://dx.doi.org/10.5588/ijtld.21.0266 Text en © 2021 The Union https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Original Articles Huddart, S. Ingawale, P. Edwin, J. Jondhale, V. Pai, M. Benedetti, A. Shah, D. Vijayan, S. TB case fatality and recurrence in a private sector cohort in Mumbai, India |
title | TB case fatality and recurrence in a private sector cohort in Mumbai, India |
title_full | TB case fatality and recurrence in a private sector cohort in Mumbai, India |
title_fullStr | TB case fatality and recurrence in a private sector cohort in Mumbai, India |
title_full_unstemmed | TB case fatality and recurrence in a private sector cohort in Mumbai, India |
title_short | TB case fatality and recurrence in a private sector cohort in Mumbai, India |
title_sort | tb case fatality and recurrence in a private sector cohort in mumbai, india |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412104/ https://www.ncbi.nlm.nih.gov/pubmed/34802496 http://dx.doi.org/10.5588/ijtld.21.0266 |
work_keys_str_mv | AT huddarts tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia AT ingawalep tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia AT edwinj tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia AT jondhalev tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia AT paim tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia AT benedettia tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia AT shahd tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia AT vijayans tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia |